

Reference: FOI.ICB-2627/170

Subject: Prostate Testing and Prostate Cancer Diagnosis

I can confirm that the ICB does hold some of the information requested; please see responses below:

QUESTION	RESPONSE
Please provide the following, for the calendar years: 2021, 2022, 2023, 2024, 2025, and 2026 to date, unless stated otherwise.	
Where held, please break each figure down by age band (18 to 25, 26 to 34, 35 to 44, 45 to 54, 55 to 64, 65 to 74, and 75 and over), by ethnicity, and by index of multiple deprivation decile. If any breakdown is not recorded, please say so.	
1. The number of PSA tests requested in primary care in each year, broken down by age band and by region.	The ICB does not hold this information
2. The number and percentage of prostate cancer diagnoses at each stage, one to four, in each year, by region.	The ICB does not hold this information. Some of this information may be available on publicly accessible data sites such as: Cancer data interactive dashboards - NDRS
3. The number of prostate cancers first identified through an emergency presentation, for example via A&E, in each year.	Please refer to Q2 response
4. The number of men diagnosed with prostate cancer through the urgent suspected cancer referral route in each year.	Please refer to Q2 response

5. The average treatment cost per patient for prostate cancer, broken down by stage at diagnosis, for each year where this is held.	This data is not held by ICB.
6. The total annual NHS spend on prostate cancer treatment in each year.	The ICB does not hold information on national spend.
7. The number of radical prostatectomies, including robot assisted procedures, and the number of radical radiotherapy courses carried out in each year, with the unit cost or tariff applied to each where held.	The ICB does not hold this information. All tariff prices are available publicly: 26-27-NHSPS-Annex-A-Prices-workbook.xlsx
8. The median and 90th percentile number of days from GP referral to first urology outpatient appointment, in each year, by trust or region for: a. The median number of days from first GP appointment to prostate MRI, and from MRI to biopsy, in each year. b. The number of men breaching the 28-day faster diagnosis standard, and the number breaching the 62-day referral to treatment standard, for suspected prostate cancer in each year.	This data is not held by ICB. Provider level data should be requested from Bristol NHS Foundation Trust: Freedom of Information Act 2000 North Bristol NHS Trust Region level data should be requested from NHS England, South West Region: NHS England » Freedom of Information Act and Environmental Information Regulations

The information provided in this response is accurate as of 7 August 2026 and has been approved for release by Caroline Dawe, Deputy Director of Performance and Delivery, Acute and Integrated Care, MHLDA and EPRR for NHS Bristol, North Somerset and South Gloucestershire ICB.